Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Overman, Michael J., Sara Lonardi, Francesco Leone, Raymond S. McDermott, Michael A. Morse, Ka Yeung Mark Wong, Bart Neyns, et al. “Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.” In Journal of Clinical Oncology, 35:519–519. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.4_suppl.519.

Full Text

Clark, Joseph I., Michael K. K. Wong, Howard L. Kaufman, Gregory A. Daniels, Michael A. Morse, David F. McDermott, Sanjiv S. Agarwala, et al. “Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.” Clin Genitourin Cancer 15, no. 1 (February 2017): 31-41.e4. https://doi.org/10.1016/j.clgc.2016.10.008.

PMID
27916626
Full Text

Devi, Gayathri R., Eun-Sil Shelley Hwang, John Stewart, Michael A. Morse, and Steven Van Laere. “Abstract B44: Immune pathway dysregulations in inflammatory breast cancer health disparity.” In Cell, Molecular, and Tumor Biology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7755.disp16-b44.

Full Text

Ren, Jun, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, et al. “Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.” Oncoimmunology 6, no. 4 (2017): e1264563. https://doi.org/10.1080/2162402X.2016.1264563.

PMID
28507788
Full Text

Osada, Takuya, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, et al. “Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.” Oncoimmunology 6, no. 6 (2017): e1315495. https://doi.org/10.1080/2162402X.2017.1315495.

PMID
28680745
Full Text

Pishvaian, Michael, Michael A. Morse, Jennifer McDevitt, Jonathan D. Norton, Song Ren, Gabriel J. Robbie, Patricia C. Ryan, Serguei Soukharev, Haifeng Bao, and Crystal S. Denlinger. “Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.” Clin Colorectal Cancer 15, no. 4 (December 2016): 345–51. https://doi.org/10.1016/j.clcc.2016.07.009.

PMID
27591895
Full Text

Alva, Ajjai, Gregory A. Daniels, Michael K. K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, et al. “Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.” Cancer Immunol Immunother 65, no. 12 (December 2016): 1533–44. https://doi.org/10.1007/s00262-016-1910-x.

PMID
27714434
Full Text

Langman, Eun L., Paul V. Suhocki, Herbert I. Hurwitz, Michael A. Morse, Rebecca A. Burbridge, Tony P. Smith, and Charles Y. Kim. “Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.” J Gastrointest Oncol 7, no. 6 (December 2016): 875–81. https://doi.org/10.21037/jgo.2016.06.13.

PMID
28078111
Full Text

Sharma, Padmanee, Margaret K. Callahan, Petri Bono, Joseph Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi N. Pillai, et al. “Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.” Lancet Oncol 17, no. 11 (November 2016): 1590–98. https://doi.org/10.1016/S1470-2045(16)30496-X.

PMID
27733243
Full Text

Overman, M. J., S. Kopetz, S. Lonardi, R. McDermott, F. Leone, J. Leach, H. J. Lenz, et al. “Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study.” In Annals of Oncology, 27:vi158, 2016. https://doi.org/10.1093/annonc/mdw370.27.

Full Text

Pages